Bharat Biotech has announced that Covid-19 vaccine Covaxin demonstrated interim clinical efficacy of 81 per cent in its phase three trial.<br />'' <br />''Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech said that Covaxin demonstrated high clinical efficacy against Covid-19 and significant immunogencity against the rapidly emerging variants.<br />'' <br />''The trials involved 25,800 participants. <br />''<br />''The first interim analysis is based on 43 cases of which 36 cases of Covid-19 were observed in the placebo group versus 7 cases observed in the Covaxin group resulting in vaccine efficacy of 81 per cent. <br />''<br />''The trials were conducted by the company with the help of Indian Council of Medical Research.<br />''<span style="color: #222222;"> </span><br />